Clinical Trial: Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07204977) titled 'Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)' on Oct. 02.

Brief Summary: Background:

Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time. Half of all people with ALS live only 3 to 5 years after diagnosis. Current drug treatments can slow the progress of the disease, but they cannot stop or reverse it.

Objective:

To test a study drug (acamprosate) in people with ALS with a mutation in the C9orf72 gene.

Eligibility:

People aged 18 year...